ABSTRACT:
Trastuzumab and Pembrolizumab, are both integral to cancer treatment. This study focused on the development of a Reverse-phase high-performance liquid chromatography technique that has been validated for simultaneous assay of Trastuzumab and Pembrolizumab using Luna Phenyl Hexyl column with UV detection at 215 nm, and the run time is 5 minutes. The retention times for Trastuzumab 2.730 min and Pembrolizumab 4.468 min were determined. The method exhibited a concentration range of 110–660 µg/ml for Trastuzumab and 12.50–75 µg/ml for Pembrolizumab. The Limit of Detection and Limit of Quantification were determined to be 0.66µg/ml and 2µg/ml for Trastuzumab,0.075 µg/ml and 0.25 µg/ml for Pembrolizumab, respectively.
Cite this article:
Alapati Sahithi, Choppala Asha Deepti. Stability indicating RP-HPLC method for the simultaneous estimation of Trastuzumab and Pembrolizumab in pharmaceutical dosage forms. Research Journal of Pharmacy and Technology. 2024; 17(5):2241-6. doi: 10.52711/0974-360X.2024.00353
Cite(Electronic):
Alapati Sahithi, Choppala Asha Deepti. Stability indicating RP-HPLC method for the simultaneous estimation of Trastuzumab and Pembrolizumab in pharmaceutical dosage forms. Research Journal of Pharmacy and Technology. 2024; 17(5):2241-6. doi: 10.52711/0974-360X.2024.00353 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2024-17-5-49
REFERENCES:
1. Yu Gao, Andrew N. Shelling, David Porter, Euphemia Leung, Zimei Wu. Stability of trastuzumab during Nano medicine formulation using SEC-HPLC coupled with polyacrylamide gel electrophoresis. Pharmaceutical Development and Technology. 2003; 28: 3-4, 288-298.
2. Baubek Spanov, Oladapo Olaleye, Nico Lingg, Arthur E.H. Bentlage, Natalia Govorukhina, Jos Hermans, Nico van de Merbel, Gestur Vidarsson, Alois Jungbauer, Rainer Bischoff. Change of charge variant composition of trastuzumab upon stressing at physiological conditions. Journal of Chromatography A. 2001; 1655, 462506.
3. Subba Rao Yarlagadda. Simultaneous method development and validation of Trastuzumab and Hyaluronidase-Oysk and its pharmacokinetic studies with LC- MS/MS .J. Pharm. Sci. & Res. 2020; 12(3): 375-380.
4. Esra Engin. Assessment of HPLC-FLD method for determination of Trastuzumab. Journal of Science and Technology. 2019; 12(1): 517-526.
5. Carola WN Damen, Hilde Rosing, Jan H.M. Schellens, Jos H. Beijnen, Quantitative aspects of the analysis of the monoclonal antibody trastuzumab using high-performance liquid chromatography coupled with electrospray mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis. 2008; 46(3): 449-455.
6. Lee Ck, Rha SY, Kim HSA. Single arm phase Ib/II trial of first-line Pembrolizumab, Trastuzumab and chemotherapy for advanced HER2-positive gastric cancer. Nat Commun. 13. 2022; 6002.
7. Janjigian Y.Y, Hechtman J.F. First-line Pembrolizumab and Trastuzumab in HER2- positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020; 21(6): 821-831.
8. Waks AG, Keenan TE, Li T. Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer.Journal for Immunotherapy of Cancer. 2022; 10: e005119.
9. Millet A, Khoudour N, Guitton J, Lebert D, Goldwasser F, Blanchet B, Machon C. Analysis of Pembrolizumab in Human Plasma by LC-MS/HRMS. method validation and comparison with elisa. Biomedicines. 2021; 9(6): 621.
10. ICH Validation of Analytical Procedures: Text and Methodology Q2 (R1), International Conference on Harmonization (2005).
11. ICH Stability Testing of New Drug Substances and Products Q1A (R2), International Conference on Harmonization (2003)